东菱克栓酶治疗不稳定型心绞痛的临床研究

目的：探讨东菱克栓酶（ＤＦ－５２１）治疗不稳定型心绞痛（ＵＡ）的疗效及安全性，为临床应用提供依据。方法：７５例ＵＡ患者于发病后第１，３，５日分别给予ＤＦ－５２１３种剂量：１０ＢＵ，５ＢＵ，５ＢＵ，溶于２００ｍｌ生理盐水中静滴。并选７７例ＵＡ患者用低分子量肝纱治疗作对照。结果：７５例患者经用ＤＦ－５２１治疗后，临床疗效总有效率８４．０％，心电图疗效总有效率６９．３％，平均起效时间为用药手５６小时，复

Clinical studies on treatment with batroxobin for unstable angina pectoris

Objective:To evaluate the clinically curative effects outcome and security of batroxobin (DF521) on unstable angina pectoris (UAP) in order to provide the evidance for clinical use.Methods:Seventyfive patients with UAP(treated group) were treated with DF521 in dosage of 10,5 and 5 BU dissolved 200 ml normal saline infused intravenously at the first day,the third day and the fifth day respectively.In control group,77 patients with UAP were treated with low molecular weight heparin.Results:After therapy with DF521 in treated group,the improvement rate of clinical symptoms was 84 0%,the effective rate of electrocardiogram was 69 3%,the reaccurrance rate was 21 3%,attack rate of acute myocardial infarction (AMI) within 3 months was 6 6%,the fibrinogen concentration in the blood was decreased significantly compared with low molecular weight heparin treatment group ( P <0 01).The average effective time was 56 hours,and sideeffects such as obvious hemorrhage and allegic reaction were not found.Conclusions:DF521 can be used in treating UAP and is effective,simple and safe.